Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

T-cells Activated More Effectively by Ellipsoidal Artificial Antigen-Presenting Cells

By BiotechDaily International staff writers
Posted on 21 Oct 2013
Image: T-cells (red) are activated more robustly when they interact with artificial antigen-presenting cells (green) that are elongated (right) versus round (left) (Photo courtesy of Dr. Karlo Perica, Johns Hopkins University).
Image: T-cells (red) are activated more robustly when they interact with artificial antigen-presenting cells (green) that are elongated (right) versus round (left) (Photo courtesy of Dr. Karlo Perica, Johns Hopkins University).
Artificial antigen-presenting cells (aAPCs) shaped like American footballs were able to activate immune system T-cells to attack and destroy cancer cells much more effectively than spherical aAPCs.

When circulating T-cells interact with APCs, they become conditioned to recognize foreign proteins, so that if the T-cells encounter those proteins again, they are able to divide rapidly to create a multitude of defensive cells that attack and destroy the cells bearing those antigens.

While both forms of aAPCs are able to express suitable levels of surface antigens, ellipsoidal particles were found to contact an appreciably greater amount of the T-cell membrane surface than did spherical particles.

Investigators at Johns Hopkins University (Baltimore, MD, USA) reported in the October 5, 2013, online edition of the journal Biomaterials that ellipsoidal biomimetic aAPCs significantly enhanced in vitro and in vivo activity above that of spherical aAPCs with similar volume and antigen content. Confocal imaging studies indicated that CD8+ T-cells preferentially migrated to and were activated by interaction with the long axis of the aAPC. Importantly, enhanced activity of ellipsoidal aAPCs was seen in a mouse melanoma model, with the football shaped particles improving survival of test mice compared to spherical aAPCs.

"The shape of the particles really seems to matter because the stretched, ellipsoidal particles we made performed much better than spherical ones in activating the immune system and reducing the animals' tumors," said senior author Dr. Jordan Green, assistant professor of biomedical engineering at Johns Hopkins University. "When immune cells in the body come in contact, they are not doing so like two billiard balls that just touch ever so slightly. Contact between two cells involves a significant overlapping surface area. We thought that if we could flatten the particles, they might mimic this interaction better than spheres and activate the T-cells more effectively. This adds an entirely new dimension to studying cellular interactions and developing new artificial APCs. Now that we know that shape matters, scientists and engineers can add this parameter to their studies."

Related Links:
Johns Hopkins University




comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).

Experimental Antimalaria Drug Induces the Immune System to Destroy Infected Red Blood Cells

An experimental drug for the treatment of malaria was found to induce morphological changes in infected erythrocytes that enabled the immune system to recognize and eliminate them. Investigators at... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.